Zimmermann, Mona L. M.
Breedt, Lucas C.
Centeno, Eduarda G. Z.
Reijneveld, Jaap C.
Santos, Fernando A. N.
Stam, Cornelis J.
van Lingen, Marike R.
Schoonheim, Menno M.
Hillebrand, Arjan
Douw, Linda
Funding for this research was provided by:
Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding (12885, 12885)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.146.086, 016.146.086, 016.146.086)
Branco Weiss Fellowship
Article History
Received: 3 October 2023
Accepted: 17 January 2024
First Online: 3 February 2024
Declarations
:
: The VUmc Medical Ethics Committee approved all studies and our research conduct followed the Declaration of Helsinki..
: Participants gave written informed consent before participation.
: Mona LM Zimmermann: The author reports no competing interests.Lucas C Breedt: The author reports no competing interests.Eduarda GZ Centeno: The author reports no competing interests.Jaap C Reijneveld:Payment for educational event: iMeedu Teaching course ‘Noord-Noordhollandse Neurologen’, iMeedu Teaching course ‘Het Centrale Brein’.Support for attending meetings or travel: Arvelle Therapeutics (manufacturer of anti-seizure medication Cenobamate), attended European Epilepsy Congress in Geneva, 2023.Fernando AN Santos: The author reports no competing interests.Cornelis J Stam: The author reports no competing interests.Marike R van Lingen: Grants or contracts from any entity: MEGIN.Menno M Schoonheim: The author reports no competing interests.Arjan Hillebrand: Grants or contracts from any entity: MEGIN, KWF Dutch Cancer Society.Linda Douw: Grants or contracts from any entity: MEGIN.